Intelligence Dossiers

• Why the convenience argument (oral vs. injection) no longer holds strategically — and what that means for AstraZeneca's communication
• The 5 most likely communication strategies — identified and prioritized with a proprietary scoring framework
• The real duel: Etcamah vs. Elacestrant (Orserdu) — both oral, both ESR1-restricted, no head-to-head
• Regulatory implications for Germany (HWG): superiority claims on a Phase II basis, mandatory ARR disclosure, MOA narratives
• Market potential scenarios: ESR1+ niche (€44–68M EU peak) vs. SERENA-4 trigger (>€500M) (Professional)

All versions are based on the same research framework. Scope of analysis and depth of strategic interpretation distinguish the tiers.

• Why the pirfenidone interaction is the central communication risk — a ~50% PK reduction sharply limits nerandomilast efficacy under pirfenidone
• The 5 most likely communication strategies — derived from FIBRONEER-IPF data (+68.8ml FVC, p<0.001) with a proprietary scoring framework
• The strategic dilemma: Boehringer Ingelheim is marketing Jascayd against its own nintedanib (Ofev) — positioning within its own portfolio
• Regulatory implications for Germany (HWG): what is communicable with PROs and what isn't — and why FVC alone isn't a convincing launch message
• Market potential: IPF niche vs. PPF expansion strategy — 3 scenarios (Bull / Base / Bear) (Professional)

All versions are based on the same research framework. Scope of analysis and depth of strategic interpretation distinguish the tiers.

• Why AbbVie is turning short effect duration (2–3 weeks) into a market development strategy — and how Boey® activates a patient group that has so far hesitated with BoNT/A products
• The 5 most likely communication strategies — first-in-class BoNT/E (score 90), short-duration positioning (score 85), and the conditional 8h onset claim (score 75)
• The structural portfolio conflict: AbbVie owns Boey® and Vistabel®/Botox® in the identical indication — the forced segmentation strategy as both communication constraint and strategic opportunity
• Regulatory implications for Germany (HWG): what's communicable about the 8h onset claim before peer-reviewed publication — and why §3 HWG regulatorily constrains the strongest launch claim
• Market potential: first-time-user niche as a new segment, 3 scenarios (Bull / Base / Bear), European market access context (Professional)

All versions are based on the same research framework. Scope of analysis and depth of strategic interpretation distinguish the tiers.